Genmab — November 2017
-
in the era of BCR kinase inhibitors, daratumumab immunotherapy opens a new horizon offering unique effects on tumor dissemination against CD38+ CLL cases. In conclusion, our results support daratumumab as a novel therapeutic approach for CD38+ CLL by not only inducing the classical FcγR-mediated cytotoxicity but also harnessing microenvironment-derived survival signaling and blocking CLL dissemination to secondary lymphoid organs.
-
Tak gentogen. Det studie du nævner står ikke i product pipeline fra q3 regnskab. Var det en del af CARINA?
-
Mere til at løfte stemningen http://www.udvalgte-ordsprog.dk/storm-p-citater.htm
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind